Literature DB >> 1790419

Apparent beneficial effects of tamoxifen on bone mineral content in patients with breast cancer: preliminary study.

W G Ryan1, J Wolter, J D Bagdade.   

Abstract

Eight postmenopausal women undergoing adjuvant treatment with tamoxifen (20 mg/day) for breast cancer had baseline pretreatment, and 6- and 12-month post-treatment dual-photon determinations of vertebral bone mineral content (BMC). BMC measured at 6 and 12 months increased over baseline in all subjects. These observations imply that women treated with tamoxifen may retain rather than surrender the protective effect of estrogen against osteoporosis.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1790419     DOI： 10.1007/bf01627077

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


  16 in total

1.  Antiestrogen and antiandrogen administration reduce bone mass in the rat.

Authors:  S Feldmann; H W Minne; S Parvizi; M Pfeifer; U G Lempert; F Bauss; R Ziegler
Journal:  Bone Miner       Date:  1989-11

2.  Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer.

Authors:  V C Jordan; N F Fritz; D C Tormey
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

3.  Amelioration of postmenopausal primary hyperparathyroidism during adjuvant tamoxifen for breast cancer.

Authors:  B Kristensen; H T Mouridsen; S N Holmegaard; I Transbøl
Journal:  Cancer       Date:  1989-11-01       Impact factor: 6.860

4.  Effects of tamoxifen on spinal bone density in women with breast cancer.

Authors:  S Turken; E Siris; D Seldin; E Flaster; G Hyman; R Lindsay
Journal:  J Natl Cancer Inst       Date:  1989-07-19       Impact factor: 13.506

5.  The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer.

Authors:  A Gotfredsen; C Christiansen; T Palshof
Journal:  Cancer       Date:  1984-02-15       Impact factor: 6.860

Review 6.  Tamoxifen in the treatment of breast cancer.

Authors:  S S Legha
Journal:  Ann Intern Med       Date:  1988-08-01       Impact factor: 25.391

7.  Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years.

Authors:  R R Love; R B Mazess; D C Tormey; H S Barden; P A Newcomb; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1988-12       Impact factor: 4.872

8.  Tamoxifen prevents the skeletal effects of ovarian hormone deficiency in rats.

Authors:  R T Turner; G K Wakley; K S Hannon; N H Bell
Journal:  J Bone Miner Res       Date:  1987-10       Impact factor: 6.741

9.  Effects of the antiestrogens tamoxifen and clomiphene on bone resorption in vitro.

Authors:  P J Stewart; P H Stern
Journal:  Endocrinology       Date:  1986-01       Impact factor: 4.736

10.  Bone mineral content of women receiving tamoxifen for mastalgia.

Authors:  I S Fentiman; M Caleffi; A Rodin; B Murby; I Fogelman
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640
View more
  5 in total

Review 1.  Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club.

Authors:  Steven Boonen; Jean-Jacques Body; Yves Boutsen; Jean-Pierre Devogelaer; Stefan Goemaere; Jean-Marc Kaufman; Serge Rozenberg; Jean-Yves Reginster
Journal:  Osteoporos Int       Date:  2005-01-26       Impact factor: 4.507

Review 2.  Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer.

Authors:  H M Bryson; G L Plosker
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

Review 3.  Calmodulin-an often-ignored signal in osteoclasts.

Authors:  John P Williams; Keith Micoli; Jay M McDonald
Journal:  Ann N Y Acad Sci       Date:  2010-03       Impact factor: 5.691

4.  Elemental composition of bone minerals in women with breast cancer treated with adjuvant tamoxifen.

Authors:  J A Kalef-Ezra; N Pavlidis; G Klouvas; A Karantanas; I Hatzikonstantinou; D Glaros
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor alpha.

Authors:  A S Levenson; I L Kliakhandler; K M Svoboda; K M Pease; S A Kaiser; J E Ward; V C Jordan
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.